Sitemap

about us

• Our History
• Company Overview
• Our Culture
• CEO Message
• Executive Leadership
• Locations
• Corporate Responsibility
• Awards & Recognitions

client support

• Resources
  • Catalog of Services for Devices & Combo Products
  • Quality Information & Certificates - U.S. Sites
  • Terms and Conditions for U.S.-based Services
• Client Portal (Login)
• U.S. Test Request/Sample Submission Forms
• Catalog Compounds

news

• Press Releases
• WuXi in Media
• WXPRESS
• For Media

careers

• Our People
• Opportunities
• Senior Management Recruitment
• Summer Internship
• Global Recruitment

contact

• Facilities
• Account Managers

services & solutions

• Discovery Services
  • Medicinal Chemistry
  • Biology
    • Oncology
    • Infectious Disease
    • CNS/Pain
    • CMD
    • Immunology and Inflammation
    • Structural Biology & Modeling
  • Safety Pharmacology
  • Drug Metabolism & Pharmacokinetics
• Lab Testing Division (LTD)
• API Development and Manufacturing (STA)
• International Discovery Service Unit (IDSU)
• Development Services
  • Pre-Formulation Development
  • Analytical Development
  • Formulation Development
  • Clinical Trial Material Manufacturing, Packaging & Labeling
• WuXi Biologics (China-Based CDMO Services)
• U.S. Biologics Testing
• U.S. Cell & Gene Therapy Services
• U.S. Medical Device Services
• Toxicology Services
  • Preclinical Services
    • General Toxicology Services
    • Genetic Toxicology Services
    • Safety Pharmacology Services
    • Immunology Services
    • Analytical and Bioanalytical Services
• Chemistry Services
  • Synthetic Chemistry
  • Analytical Chemistry
  • Separation Technology
  • Peptide Synthesis
  • Catalog Reagents
  • Compound Management
  • eCommerce
• Bioanalytical Services
• Clinical & Regulatory Services
  • Clinical Trial Management
  • DM and Biostatistics
  • Regulatory Affairs
  • Professional SMO - MedKey
• Genome Center
• Biological Reagents - Abgent
  • Unsurpassed Development Capabilities
  • ELITE™ Custom Antibody Service
• WuXi Venture Fund